Group 1: Financial Performance and Dividends - The company did not achieve profitability in 2024, thus not meeting the conditions for cash dividends [2] - Future dividend considerations will depend on factors such as shareholder returns, profitability, cash flow, and funding needs [2] Group 2: Product Development - The company has submitted a registration application for human milk oligosaccharides and is actively promoting its industrialization [2] Group 3: Trade Policy Impact - U.S. trade policies have had a certain impact on company orders, with a 20% tariff on Vitamin B2 products remaining in place [2] - Future changes in U.S. tariffs are uncertain, and the company will closely monitor policy developments to manage risks [2] Group 4: Operational Goals - As of the end of May 2025, the company is focused on achieving its operational targets under the "second entrepreneurship" high-quality development strategy [2] - The company aims to enhance product competitiveness, integrate resources, optimize existing assets, strengthen compliance management, and deepen management reforms [2] Group 5: Market Orders - Orders for the company's vitamin products in the European market remained stable in 2025 [3]

Group 1: Company Performance and Financials - The company's revenue from exports accounted for 39.15% of total revenue in 2024, with the U.S. market contributing approximately 35% of export sales [2] - As of March 2025, the company's revenue indicators were slightly below schedule, with a net profit indicator showing a loss of 28.20% year-on-year [3] Group 2: Product Development and Research - The company is actively advancing its human milk oligosaccharides project in collaboration with Jiangnan University, aiming for product approval and market launch [2] - The company has obtained EU registration for riboflavin and riboflavin phosphate products, which are now authorized for sale in the EU market [3] Group 3: Strategic Initiatives and Future Plans - The company is committed to a "second entrepreneurship" strategy focused on high-quality development, enhancing product competitiveness, and optimizing resource allocation [3] - In response to national "dual carbon" goals, the company is integrating sustainable development into its operations and has been recognized as a national-level green factory [3] Group 4: Innovation and Technology - Currently, the company does not utilize AI in drug research but is monitoring developments in this area for future applications [3] - The company collaborates with universities and research institutions to develop new products and promote the industrialization of synthetic biology projects [2]